Parv Barot

MARCH'S BEST FEATURED EDITORIAL Hibernating Squirrels May Hold Clues To Treating Heart Failure Examining natural mechanisms of cardiac repair in hibernating squirrels has provided insight into biological pathways that could help develop a therapeutic for HFpEF.

Join this live discussion designed for scientists and leaders seeking to understand where open-source AI is delivering real impact today—and why AI is no longer optional for staying competitive in drug discovery. Registration is free, more info here. By injecting lipid-based nanoparticles encapsulating mRNA and encoding the CAR directly into the bloodstream, developers can effectively reprogram the patient's own immune cells in situ.

By Parv Barot The clinical success of autologous CAR-T cell therapies, such as Kymriah and Yescarta, has been hailed as a "penicillin moment" for cancer. Yet, the operational reality of these therapies is often described as a logistical nightmare and uncertain. The standard "vein-to-vein" cycle — harvesting T cells via leukapheresis, shipping them to a centralized facility for viral transduction and expansion, and returning them for infusion — typically spans three to four weeks.